Put Your (Frozen) Eggs in the Bank: Welcome to the Bioeconomy
By Victoria Turk,
Motherboard
| 02. 23. 2015
[Quotes CGS Fellow Lisa Ikemoto]
Untitled Document
Emerging reproductive technologies are helping address medical issues that affect fertility and give us more choice when it comes to family planning. But they also risk presenting our bodies from a new perspective: as a commodity to be banked, bought, and sold.
These social and political implications are the subject of a commentary in the Journal of Law and the Biosciences, by UC Davis bioethicist Lisa Ikemoto. She writes that “supply of the cells and bodies necessary for assisted reproductive technology use depends on market thinking and structural inequality.” In other words, the market depends on a discrepancy between rich and poor: Those who can afford to buy, and those who are in enough financial need that they will sell their eggs and sperm.
“The whole practice of egg donation, sperm donation, surrogacy, and I think in addition to that egg freezing not only for one’s own self but as a way of expanding egg banking for others’ use: All that relies on wealth inequality,” Ikemoto told me in a phone interview.
Her piece focuses on egg...
Related Articles
By Sophie Alexander and Ike Swetlitz, Bloomberg | 06.25.2025
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to one of the most controversial technologies in medicine.
Bootstrap Bio...
By Elise Kinsella, ABC News | 06.15.2025
When *Sarah and her partner needed fertility testing, it was Monash IVF that the pair turned to.
"Having a quick browse online, Monash IVF was one of the most prominent ones that came up on Google search and after contacting...
By Hilary Bowman-Smart and Craig Stanbury, The Conversation | 06.12.2025
By Antonio Regalado, MIT Technology Review | 06.05.2025
Brian Armstrong, the billionaire CEO of the cryptocurrency exchange Coinbase, says he’s ready to fund a US startup focused on gene-editing human embryos. If he goes forward, it would be the first major commercial investment in one of medicine’s most...